Timothy Caulfield, a law professor at the University of Alberta, said that health influencers increasingly engage in scienceploitation: they generate hype by making speculative claims that extrapolate wildly from limited research
Genetic testing not standard but may explain differential peptide responses
Preclinical Evidence Across Tissue Types Soft Tissue (Muscle, Tendon, and Ligament) Models: Many rodent studies have examined BPC-157 in models of musculoskeletal injury: In rat tendon and ligament injury experiments, administration of BPC-157 accelerated collagen organization and improved measures of biomechanical integrity relative to untreated controls (4)
The FDAs own language makes it clear: Compounded drugs containing BPC-157 may pose risk for immunogenicity and may have complexities with regard to peptide-related impurities and API characterization. In plain terms, the FDA is worried about shady, unregulated research-use-only peptides sold online not about what happens when BPC-157 is responsibly compounded, tested for purity, and dispensed under medical supervision
The main difference comes down to one critical factor: absorption
